Study results support the role of functional dystrophin and suggest that delandistrogene moxeparvovec stabilizes or slows ...

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).

Panelists discuss how selecting an optimal combination of screening assessments for Alzheimer disease requires careful consideration of test sensitivity, specificity, accessibility, cost-effectiveness ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

Panelists discuss how significant knowledge gaps among nonspecialist providers—particularly regarding differential diagnosis, interpretation of cognitive assessments, and awareness of treatment ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Patients who did not complete a distress screener were also less likely to receive autologous stem cell transplants.